

## // 120 YEARS OF SCIENCE AND RESEARCH //

The Paul-Ehrlich-Institut continues the tradition of Paul Ehrlich (1854-1915), who founded the institute and whose name it bears. Paul Ehrlich's scientific work focused on the testing and development of medicinal products. In 1908, he was awarded the Nobel Prize for Medicine in recognition of his work in the field of immunology.

- 1896** Foundation of the "Institute for Serum Research and Serum Testing" in Steglitz, Berlin; Paul Ehrlich was its first director
- 1899** Relocation to Frankfurt as the newly established "Royal Institute for Experimental Therapy"
- 1947** Renamed the Paul-Ehrlich-Institut, an agency of the state of Hesse
- 1972** Established as an independent senior federal authority
- 1990** Inauguration of the new Institute in Langen
- 1994** Responsibility for blood and blood products
- 2000** Establishment of a testing laboratory for in vitro diagnostics (PEI-IVD)
- 2004** New official duty: approval of clinical trials
- 2005** Designation as WHO Collaborating Centre for Blood Products and in vitro Diagnostic Devices
- 2007** Responsibility for tissue and tissue preparations
- 2011** Responsibility for all vaccines for veterinary use
- 2013** Designation as WHO Collaborating Centre for Standardization and Evaluation of Vaccines
- 2014** New official duty: approval of field trials of immunological veterinary medicinal products

>> [www.pei.de/history](http://www.pei.de/history)

## // MAJOR EMPLOYER IN THE RHINE- MAIN REGION //

The Paul-Ehrlich-Institut employs approximately 800 people, including around 317 scientists and 46 medical professionals. 32 trainees receive vocational training in nine professional areas, and the PEI offers an integrated work-study programme. The PEI attaches special importance to the combination of medicinal product testing, assessment and research. Members of staff are characterised by their expertise, efficiency and commitment, as well as by their flexibility. The Institute actively promotes and successfully implements work/life balance, equal opportunities and the inclusion of staff members with disabilities.

>> [www.pei.de/vacancies](http://www.pei.de/vacancies)



>> [www.pei.de/directions](http://www.pei.de/directions)



The Paul-Ehrlich-Institut  
is an Agency of the  
German Federal  
Ministry of Health.

Paul-Ehrlich-Institut  
Paul-Ehrlich-Straße 51-59  
63225 Langen, Germany  
Phone +49 6103 77-0  
Fax +49 6103 77-1234  
e-mail [pei@pei.de](mailto:pei@pei.de)  
>> [www.pei.de](http://www.pei.de)



// FEDERAL INSTITUTE  
FOR VACCINES AND  
BIOMEDICINES //

July 2016



## // FOCUS ON HEALTH //

As the Federal Institute for Vaccines and Biomedicines, the Paul-Ehrlich-Institut (PEI) sets high standards on the quality, efficacy and safety of biomedicines for people and animals. The PEI monitors biomedicines from their development to their application:

- Scientific advice at national and international level
- Approval of clinical trials and marketing authorisation-related field trials
- Marketing authorisation and official batch testing
- Recording and evaluation of adverse reactions

### BIOMEDICINES FOR HUMAN USE

- Vaccines
- Biotechnological medicinal products and medicines containing antibodies
- Allergens for therapy and diagnostics
- Blood and blood products
- Tissue preparations
- Advanced therapy medicinal products (ATMP): Cell and gene therapeutics and tissue engineering products

### BIOMEDICINES FOR VETERINARY USE

- Vaccines and sera

>> [www.pei.de/medicinalproducts](http://www.pei.de/medicinalproducts)

## // RECOGNISED EXPERTISE GAINED THROUGH RESEARCH //

The PEI has gained international recognition for its combination of medicinal product evaluation and testing, regulatory research and basic research. Scientists at the PEI develop new methods and high quality standards for the experimental batch testing of vaccines and biomedicines. In addition, they analyse the causes of unexpected adverse events, thus making an essential contribution to preventing them in future. High-level basic research enables a better understanding of mechanisms of action and paves the way for new therapeutic approaches with biomedicines.

### RESEARCH AREAS

- Regulatory research & innovative product testing
- Pathogen-host & biomedicine-organism interaction
- Experimental vaccines, therapies & diagnostics

>> [www.pei.de/research](http://www.pei.de/research)

## // ADVICE TO HEALTH POLICY DECISION-MAKERS //

Its research activities, scientific expertise and networking at national and international level make the PEI an expert point of contact for the worlds of science, medicine, politics, and industry.

## // AN INSTITUTE WITH INTERNATIONAL DIMENSIONS //

### INFLUENTIAL IN EUROPE

In the context of national and international cooperation, the PEI makes an active contribution to drafting laws and guidelines and helps shape the regulatory framework for vaccines and biomedicines in Europe. The PEI is also increasingly acting at an international level in the regulation of medicinal products: many vaccines and biomedicines receive EU-wide marketing authorisation. PEI scientists, together with other European experts, carry out the scientific benefit/risk assessment at the European Medicines Agency (EMA). The PEI is represented on important EMA committees and working parties and plays a major role throughout Europe.

### WHO COLLABORATING CENTRES

Two collaborating centres of the World Health Organization (WHO) are located at the Paul-Ehrlich-Institut:

- Collaborating Centre for Blood Products and in vitro Diagnostic Devices (IVD) since 2005
- Collaborating Centre for Standardization and Evaluation of Vaccines since 2013

>> [www.pei.de/who-cc-en](http://www.pei.de/who-cc-en)

### PEI-IVD: TESTING LABORATORY FOR IN VITRO DIAGNOSTICS

In collaboration with Notified Bodies and other organisations, the testing laboratory examines the efficacy and quality of in vitro diagnostic devices (IVDs) in accordance with the Medical Devices Act. Products tested at the PEI mainly include high-risk IVDs, e.g. testing systems for the identification of pathogens such as HIV or hepatitis viruses, as well as blood group typing reagents.

>> [www.pei.de/ivd-en](http://www.pei.de/ivd-en)

